摘要
背景:1999年鉴定的磷酸二酯酶10(PDE 10)家族主要表达于大脑,尤其是纹状体、中等棘神经元、伏隔核和嗅结节。PDE 10抑制剂(PDE 10-IS)是一门概念合理的药物化学学科,在治疗精神疾病和神经退行性疾病方面具有潜在的应用价值。 目的:在文献综述的基础上,综述PDE 10作为精神病学和神经退行性药物发现的合理靶点的细胞和分子生物学研究进展。本文从药物化学的角度,从茶碱和咖啡因类似物、罂粟碱和二甲氧基邻苯二酚型PDE 10-is、TP-10、MP-10、MP-10/罂粟碱/喹唑啉系列抑制剂入手,对PDE 10-进行了分类。作者根据PDE10A在精神分裂症、帕金森病、亨廷顿病和阿尔茨海默氏病动物模型中的作用,对PDE10A作为精神科和神经退行性疾病的治疗策略进行了近期的研究。本文还介绍了PDE 10的药理数据,认为PDE 10是治疗认知缺陷、肥胖和抑郁的可能药物。此外,根据临床试验的结果,总结了PDE 10-是药物发现的当前策略。作者还介绍了PDE 10配合物与新型抑制剂的晶体结构的最新研究。
关键词: 磷酸二酯酶10,PDE 10抑制,中枢神经系统药物开发,抗精神病药物,精神分裂症,帕金森病,认知。
Current Medicinal Chemistry
Title:Phosphodiesterase 10 Inhibitors - Novel Perspectives for Psychiatric and Neurodegenerative Drug Discovery
Volume: 25 Issue: 29
关键词: 磷酸二酯酶10,PDE 10抑制,中枢神经系统药物开发,抗精神病药物,精神分裂症,帕金森病,认知。
摘要: Background: The phosphodiesterase 10 (PDE10) family, identified in 1999, is mainly expressed in the brain, particularly in the striatum, within the medium spiny neurons, nucleus accumbens, and olfactory tubercle. Inhibitors of PDE10 (PDE10-Is) are a conceptually rational subject for medicinal chemistry with potential use in the treatment of psychiatric and neurodegenerative diseases.
Objective: This review is based on peer-reviewed published articles, and summarizes the cellular and molecular biology of PDE10 as a rational target for psychiatric and neurodegenerative drug discovery. Here, we present the classification of PDE10-Is from a medicinal chemistry point of view across a wide range of different, drug-like chemotypes starting from theophylline and caffeine analogs, papaverine and dimethoxy catechol type PDE10-Is, TP-10, MP-10, MP-10/papaverine/quinazoline series inhibitors, and ending with the newest inhibitors obtained from fragment-based lead discovery (FBLD). The authors have collated recent research on inhibition of PDE10A as a promising therapeutic strategy for psychiatric and neurodegenerative diseases, based on its efficacy in animal models of schizophrenia, Parkinson’s, Huntington’s, and Alzheimer’s diseases. This review also presents pharmacological data on PDE10-Is as possible therapeutics for the treatment of cognitive deficits, obesity and depression. Moreover, it summarizes the current strategies for PDE10-Is drug discovery based on the results of clinical trials. The authors also present the latest studies on crystal structures of PDE10 complexes with novel inhibitors.
Export Options
About this article
Cite this article as:
Phosphodiesterase 10 Inhibitors - Novel Perspectives for Psychiatric and Neurodegenerative Drug Discovery, Current Medicinal Chemistry 2018; 25 (29) . https://dx.doi.org/10.2174/0929867325666180309110629
DOI https://dx.doi.org/10.2174/0929867325666180309110629 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nutritional Support in Cancer
Current Nutrition & Food Science New Insights about Regulatory T Cells Distribution and Function with Exercise: The Role of Immunometabolism
Current Pharmaceutical Design Vagotomy and Gastric Tumorigenesis
Current Neuropharmacology Oxidative Stress in Schizophrenia
Current Neuropharmacology Role of Nitrosative Stress and Activation of Poly(ADP-ribose) Polymerase-1 in Cardiovascular Failure Associated with Septic and Hemorrhagic Shock
Current Vascular Pharmacology Copper and Neurotoxicity in Autism Spectrum Disorder
Current Pharmaceutical Design Microbial Biotransformation: Recent Developments on Steroid Drugs
Recent Patents on Biotechnology Dosage and Passage Dependent Neuroprotective Effects of Exosomes Derived from Rat Bone Marrow Mesenchymal Stem Cells: An In Vitro Analysis
Current Gene Therapy The Recent Expansion in the Australian Cocaine Market: Who are the New Users and What are the Harms?
Current Drug Abuse Reviews Potential for Treatment of Neurodegenerative Diseases with Natural Products or Synthetic Compounds that Stabilize Microtubules
Current Pharmaceutical Design Melanin-Concentrating Hormone Receptor 1 Antagonists: A New Perspective for the Pharmacologic Treatment of Obesity
Current Medicinal Chemistry Vascular Risk Factors and Alzheimer’s Disease Pathogenesis: Are Conventional Pharmacological Approaches Protective For Cognitive Decline Progression?
CNS & Neurological Disorders - Drug Targets Formulation and In Vitro Evaluation of Gelatin Nanospheres for the Oral Delivery of Selegiline
Current Nanoscience ADP-Ribosyl Cyclase as a Therapeutic Target for Central Nervous System Diseases
Central Nervous System Agents in Medicinal Chemistry Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance
Current Medicinal Chemistry The Role of Diabetes Mellitus in Sexual and Reproductive Health: An Overview of Pathogenesis, Evaluation, and Management
Current Diabetes Reviews Perspectives on Developing Small Molecule Inhibitors Targeting HIV-1 Integrase
Mini-Reviews in Medicinal Chemistry Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Preface:
Central Nervous System Agents in Medicinal Chemistry Anti-Parkinsonian Effects of Nurr1 Activator in Ubiquitin-Proteasome System Impairment Induced Animal Model of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets